简介：

简介：Ovariancancerisoneofthemostlethalmalignantgynecologicaltumors.Morethan70%ofpatientswithovariancancerarediagnosedatadvancedstage.The5-yearsurvivalinpatientswithadvancedovariancancerislessthan30%becauseofthelackofeffectivebiomarkersfordiagnosis,prognosis,andpersonalizedtreatment.MicroRNA(miR)isaclassofsmallnoncodingRNAsthatnegativelyregulategeneexpressionprimarilythroughpost-transcriptionalrepression.ManystudiesontissuemiRinovariancancerhavebeencarriedoutandshowgreatpotentialinclinicalpractice.However,tissuesamplesarenoteasilyavailablebecausesamplingcausesinjury.Researchershavestartedtofocusonplasma/serummiR,assumingthatbloodsamplesmayreplacetissuesamplesinmiRresearchinthefuture.Plasma/serummiRresearchisstillinitsearlystages.Studiesonitsfunctionintheearlydiagnosisofovariancancerhaveachievedsomeprogress,butplasma/serummiRprofilingforprognosisandpersonalizedtreatmentofovariancancerremainsunknown.Athoroughunderstandingofthefunctionofplasma/serummiRinovariancancerwillfacilitateearlydiagnosisandimprovetreatmentforovariancancer.

简介：Objectives:ToexploretheprognosticrelevanceofthenumberandratioofmetastaticlymphnodesinresectedCarcinomaoftheampullaofVater(CAV).Methods:Theclinicaldataof155patientswhounderwentpancreaticoduodenectomy(PD)forcanceroftheampullaofVaterbetweenJanuary1990andDecember2010wereretrospectivelyanalyzed.KaplanMeiermethodwasusedinsurvivalanalysisandLogrankmethodincomparison.MultivariateanalysiswasperformedusingCoxproportionalhazardsmodel.Results:Amongthese155patients,thein-hospitalmortalityratewas4.5%,lymphnodepositivediseasewas21.3%,andthe5-yearsurvivalratewas51.6%.Patientswithalymphnoderatio(LNR)>20%weremorelikelytohavetumordifferentiation,depthofduodenalinvolvement,depthofpancreaticinvasion,T-stageandTNM-Stage.ThenumberofthemetastaticlymphnodesisimportantprognosticfactorsoftheCAV.Univariateanalysisshowedthatthefactorsassociatedwiththeprognosisincludedtumorsize(P=0.036),tumordifferentiation(P=0.019),LNR(P=0.032),numberofmetastaticlymphnodes(P=0.024),lymphnodemetastasis(P=0.03),depthofpancreaticinvasion(P=0.001),T-stage(P=0.002),TNMstage(P=0.001),elevatedCA19-9(P=0.000),andjaundice(P=0.021).Multivariateanalysisshowedthatthefactorsassociatedwiththeprognosiswerethenumberofmetastaticlymphnodes(P=0.032;RR:1.283;95%CI:1.022-1.611),tumorsize(P=0.043;RR:1.736;95%CI:1.017-2.963),andelevatedCA19-9(P=0.003;RR:3.247;95%CI:1.504-7.010).Conclusions:LNRisausefulfactorforpredictingtheprognosisoftheradicaltreatmentforCAV,whereasthenumberofmetastaticlymphnodesisthemostimportantfactor.Furtherresearchonthelocations,number,andLNRwillbeclinicallymeaningfultoimprovesurvivalinpatientswithCAV.

简介：Objective:Chemotherapyisthestandardtreatmentforsmall-celllungcancer(SCLC),andleukopeniaisacommonsideeffect.Thisstudyassesseswhetherchemotherapy-inducedleukopeniaisapredictorofefficacyandwhetheritisassociatedwiththesurvivalofSCLCpatients.Methods:Aretrospectiveanalysiswasconductedondatafrom445patientswithSCLCwhoreceivedstandardchemotherapyfor4to10cycles.TheWorldHealthOrganizationgradingsystemclassifiesleukopeniaduringchemotherapyasfollows:absent(grade0),mild(grades1and2),orsevere(grades3and4).Theprimaryendpointisoverallsurvival(OS).Results:Theassociationbetweenchemotherapy-inducedleukopeniaandOSwasassessed.AccordingtoamultivariateCoxmodelwithtime-varyingcovariates,thehazardratioofdeathwassignificantlyloweramongpatientswithmildleukopeniathanamongpatientswithsevereleukopeniaat0.687(0.506to0.943)and1.414(1.147to1.744),respectively.Themediansurvivalwas13months(95%CI:11to15months)forpatientswhodidnotexperienceleukopenia,17months(95%CI:14to18months)forthosewithmildleukopenia,and14months(95%CI:13to16months)forthosewithsevereleukopenia(absentvs.mildvs.severeleukopenia,P=0.047).Conclusion:LeukopeniaduringchemotherapyisassociatedwiththesurvivalofSCLCpatients.Mildleukopeniaisstronglyassociatedwithlongersurvivaltime.

简介：Objective:Thisstudyaimstoexploretheclinicopathologiccharacteristicsandprognosticfactorsofgastriccancerpatientswithmetachronousovarianmetastasis.Methods:Clinicopathologicdatawerecollectedfrom63post-operativegastriccancerpatientswithmetachronousovarianmetastasis.ThepatientswereadmittedtotheCancerInstituteandHospital,ChineseAcademyofMedicalScienceandPekingUnionMedicalCollegebetweenJanuary1999andDecember2011.Alog-ranktestwasconductedforsurvivalanalysis.Possibleprognosticfactorsthataffectsurvivalwereexaminedbyunivariateanalysis.ACoxregressionmodelwasusedformultivariateanalysis.Results:Theincidenceofovarianmetastasiswas3.4%withameanageof45years.Upto65.1%ofthepatientswerepre-menopausal.Themeanintervalbetweenovarianmetastasisandprimarycancerwas16months.Lowlydifferentiatedcarcinomarankedfirstintheprimarygastriccancers.Themajorityoflesionsoccurredintheserousmembrane(87.3%).ThemetastaticsitesincludedN2-3lymphnodes(68.3%),bilateralovaries(85.7%),andperitonealmembrane(73%).Totalresectionofmetastaticsiteswasperformed(31.7%).Theoverallmediansurvivalwas13.6months,whereastheoverall1-,2-,and3-yearsurvivalrateswere52.5%,22.0%,and9.8%,respectively.The5-yearsurvivalratewaszero.Univariateanalysisshowedthatthepatientprognosiswascorrelatedwithmetastaticperitonealseeding,vasculartumorembolus,rangeoflesionexcision,andmodeofcomprehensivetreatmentwithadjuvantchemotherapy(P<0.05).Multivariateanalysisindicatedthatmetastaticperitonealseedingwasanindependentprognosticfactorforgastriccancerpatientswithovarianmetastasis(P<0.01).Conclusion:Effectivecontrolofperitonealseeding-inducedmetastasisisimportantforimprovingtheprognosisofgastriccancerpatientswithovarianmetastasis.